London, September 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with CellCentric and is pleased to announce the placement of Andy Fergus as Chief Development Officer. Andy joined CellCentric in September 2024, and is Boston based.CellCentric’s mission is to transform outcomes for people living with specific cancers, notably relapsed refractory multiple myeloma, as quickly and effectively as possible. The clinical-stage biotech company focuses on the development of inobrodib,…
PACE (Pathways to Antimicrobial Clinical Efficacy) has today launched its second funding round with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of antimicrobial resistance (AMR).
PACE is one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic discovery. The pioneering partnership between LifeArc, Medicines Discovery Catapult (MDC) and Innovate UK is driving the development of new tests and treatments to tackle deadly AMR, which…
Paris, France - A new research study published in Nature Communications highlights how Depixus’ scalable single molecule technology can provide detailed mechanistic insights into RNA-ligand binding, supporting the development of novel therapeutics.
Based on magnetic force spectroscopy (MFS), Depixus’ large scale interactomics platform is the first analytical technology capable of exploring dynamic biomolecular interactions both in real time and from thousands of individual molecules in parallel.
The study was led by Dr. John “Jay” Schneekloth, Jr. a leading expert in RNA-targeted drug…
Oxford, UK - British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors.
The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as healthy volunteers. Participants will be asked to donate a small amount of blood up to five times over the course of one year, and provide information about their health.
The ETCh study is rooted in the well-established concept that long-term survivors have beaten cancer due to…
AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity.
Immunofluorescence (IF) allows detection and localization of antigens in diverse types of tissues in various cell preparations. The technique provides excellent sensitivity and amplification of signal by comparison to immunohistochemistry. However, traditional IF staining is a labor intensive, multi-step…
Recent research indicates that the rate of global warming caused by human activity is at an all-time high.* In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.
This year, Pioneer is accelerating the development of planetary health innovations through a comprehensive programme of events, a “Golden Ticket” competition, venture development support, specialist lab space, and access to its expert network.
“With global temperatures on the rise, supporting innovations…
Sandwich, Kent, UK / 24 September 2024 / A group of former Pfizer employees have successfully created their own businesses based at and supported by Discovery Park, a thriving life sciences community in Kent. The new businesses are all contract research organisations, namely Biowaived, Matheus Engineering and Particology Ltd. Their launch has been supported by Pfizer’s Pharmaceutical Sciences Small Molecule (PSSM) division, with contracts for work to build their initial viability and momentum. The opportunity to establish these new businesses emerged from Pfizer’s cost realignment…
The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has today announced the first cohort of awardees of its Collaborative Discovery Programme (CDP) funding.
The £3 million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections in people with CF.
CF affects over 162,000 people globally. People with CF are affected by life-threatening lung infections that can permanently change lung function and reduce their quality of life. Growing resistance to antimicrobials and lack of effective…
Laurence Reid joins as Chairman, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Third Rock Ventures
Brad Crutchfield appointed as Non-Executive Director, previously 10x Genomics, QIAGEN, Illumina, and Bio-Rad Laboratories
Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of…